CB1 cannabinoid receptor-G protein association: A possible mechanism for differential signaling

Chemistry and Physics of Lipids

Volumn 121, Issue 1-2, 2002, Pages 91-109

  Mukhopadhyay, Somnath ^a   Shim, Joong Youn ^a,b   Assi, Abdel Azim ^a   Norford, Derek ^a   Howlett, Allyn C ^a  

^a NORTH CAROLINA CENTRAL UNIVERSITY   (United States)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Cannabinoid; Protein; Receptor

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 5 (1,1 DIMETHYLHEPTYL) 2 (3 HYDROXY 7 HYDROXYMETHYLDECAHYDRO 1 NAPHTHYL)PHENOL; ADENYLATE CYCLASE; ANANDAMIDE; CALCIUM CHANNEL N TYPE; CALCIUM ION; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; DEXANABINOL; DRONABINOL; ENZYME INHIBITOR; G PROTEIN COUPLED RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE;

CARBOXY TERMINAL SEQUENCE; CELL DIFFERENTIATION; CONFERENCE PAPER; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; HUMAN; NEUROBLASTOMA; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ADENYLATE CYCLASE; AMINO ACID SEQUENCE; ANIMALS; CALCIUM CHANNELS; CANNABINOIDS; CELL DIFFERENTIATION; GTP-BINDING PROTEINS; HETEROTRIMERIC GTP-BINDING PROTEINS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NITRIC OXIDE; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; SIGNAL TRANSDUCTION;

EID: 0037207072     PISSN: 00093084     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-3084(02)00153-6     Document Type: Conference Paper

References (99)

1. Augusti-Tocco G., Sato G. Establishment of functional clonal lines of neurons from mouse neuroblastoma. Proc. Natl. Acad. Sci. USA. 64:1969;311-315.
2. Baker D., Pryce G., Croxford J.L., Brown P., Pertwee R.G., Huffman J.W., Layward L. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature. 404:2000;84-87.
3. Baldwin J.M., Schertler G.F., Unger V.M. An alpha-carbon template for the transmembrane helices in the rhodopsin family of G-protein-coupled receptors. J. Mol. Biol. 272:1997;144-164.
4. Benda P., Someda K., Messer J., Sweet W.H. Morphological and immunochemical studies of rat glial tumors and clonal strains propagated in culture. J. Neurosurg. 34:1971;310-323.
5. Bergsbaken C.L., Sommers S.L., Law P.Y. Effect of forskolin and isobutylmethylxanthine on delta-opioid receptor activity in neuroblastoma x glioma NG108-15 cells. J. Pharmacol. Exp. Ther. 264:1993;1474-1483.
6. Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., Shindyalov I.N., Bourne P.E. The protein data bank. Nucleic Acids Res. 28:2000;235-242.
7. + exchanger NHE-1 isoform via Gi-mediated mitogen activated protein kinase signaling transduction pathways. FEBS Lett. 449:1999;61-65.
8. 1 induces krox-24 expression in human astrocytoma cells. J. Biol. Chem. 270:1995;13973-13980.
9. 1. Biochem. J. 312:1995;637-641.
10. Breivogel C.S., Griffin G., Di M.V., Martin B.R. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol. Pharmacol. 60:2001;155-163.
11. Caulfield M.P., Brown D.A. Cannabinoid receptor agonists inhibit Ca current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism. Br. J. Pharmacol. 106:1992;231-232.
12. Childers S.R., Deadwyler S.A. Role of cyclic AMP in the actions of cannabinoid receptors. Biochem. Pharmacol. 52:1996;819-827.
13. Chin C.N., Lucas-Lenard J., Abadji V., Kendall D.A. Ligand binding and modulation of cyclic AMP levels depend on the chemical nature of residue 192 of the human cannabinoid receptor 1. J. Neurochem. 70:1998;366-373.
14. 2+-inhibitable adenylyl cyclase in non-excitable cells. J. Biol. Chem. 270:1995;1149-1155.
15. Colasanti M., Persichini T., Venturini G., Polticelli F., Musci G. Modulation of the nitric oxide pathway by copper in glial cells. Biochem. Biophys. Res. Commun. 275:2000;776-782.
16. Deadwyler S.A., Hampson R.E., Mu J., Whyte A., Childers S. Cannabinoids modulate voltage sensitive potassium A-current in hippocampal neurons via a cAMP-dependent process. J. Pharmacol. Exp. Ther. 273:1995;734-743.
17. DeBernardi M.A., Munshi R., Yoshimura M., Cooper D.M., Brooker G. Predominant expression of type-VI adenylate cyclase in C6-2B rat glioma cells may account for inhibition of cyclic AMP accumulation by calcium. Biochem. J. 293:1993;325-328.
18. Derkinderen P., Toutant M., Burgaya F., Le Bert M., Siciliano J.C., de F.V., Gelman M., Girault J.A. Regulation of a neuronal form of focal adhesion kinase by anandamide. Science. 273:1996;1719-1722.
19. Devane W.A., Dysarz F.A. III, Johnson M.R., Melvin L.S., Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34:1988;605-613.
20. 1 receptor-mediated inhibition of inducible nitric oxide synthase protein expression in C6 rat glioma cells. J. Neurochem. 78:2001;835-841.
21. 2+ entry. J. Biol. Chem. 273:1998;9297-9305.
22. Feinstein D.L., Galea E., Cermak J., Chugh P., Lyandvert L., Reis D.J. Nitric oxide synthase expression in glial cells: suppression by tyrosine kinase inhibitors. J. Neurochem. 62:1994;811-814.
23. Feinstein D.L., Galea E., Reis D.J. Suppression of glial iNOS expression by tyrosine kinase inhibitors. Ann. NY Acad. Sci. 738:1994;325-328.
24. Felder C.C., Briley E.M., Axelrod J., Simpson J.T., Mackie K., Devane W.A. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc. Natl. Acad. Sci. USA. 90:1993;7656-7660.
25. 1 receptor to stimulation of cAMP accumulation. J. Pharmacol. Exp. Ther. 284:1998;291-297.
26. 2 receptors. Mol. Pharmacol. 48:1995;443-450.
27. Fields A., Gafni M., Oron Y., Sarne Y. Multiple effects of opiates on intracellular calcium level and on calcium uptake in three neuronal cell lines. Brain Res. 687:1995;94-102.
28. Fields A., Sarne Y. The stimulatory effect of opioids on cyclic AMP production in SK-N-SH cells is mediated by calcium ions. Life Sci. 61:1997;595-602.
29. Fimiani C., Mattocks D., Cavani F., Salzet M., Deutsch D.G., Pryor S., Bilfinger T.V., Stefano G.B. Morphine and anandamide stimulate intracellular calcium transients in human arterial endothelial cells: coupling to nitric oxide release. Cell Signal. 11:1999;189-193.
30. Galve-Roperh I., Sanchez C., Cortes M.L., del Pulgar T.G., Izquierdo M., Guzman M. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat. Med. 6:2000;313-319.
31. Galve-Roperh I., Sanchez C., Guzman M. Signaling at zero G: a comment. Trends Biochim. Sci. 26:2001;533.
32. Garibay J.L., Kozasa T., Itoh H., Tsukamoto T., Matsuoka M., Kaziro Y. Analysis by mRNA levels of the expression of six G protein alpha-subunit genes in mammalian cells and tissues. Biochim. Biophys. Acta. 1094:1991;193-199.
33. Gilman A.G., Minna J.D. Expression of genes for metabolism of cyclic adenosine 3′:5′-monophosphate in somatic cells. I. Responses to catecholamines in parental and hybrid cells. J. Biol. Chem. 248:1973;6610-6617.
34. 1 receptor. J. Neurosci. 17:1997;5327-5333.
35. 2 receptors. Mol. Pharmacol. 56:1999;1362-1369.
36. 1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt. Biochem. J. 347:2000;369-373.
37. Hamprecht B. Structural, electrophysiological, biochemical, and pharmacological properties of neuroblastoma-glioma cell hybrids in cell culture. Int. Rev. Cyto. 149:1977;99-170.
38. Hanoune J., Defer N. Regulation and role of adenylyl cyclase isoforms. Annu. Rev. Pharmacol. Toxicol. 41:2001;145-174.
39. Higashijima T., Bumier J., Ross E.M. Regulation of Gi and Go by mastoparan, related amphiphilic peptides, and hydrophobic amines. Mechanism and structural determinants of activity. J. Biol. Chem. 265:1990;14176-14186.
40. Higashijima T., Ross E.M. Mapping of the mastoparan-binding site on G proteins. Cross-linking of [125I-Tyr3,Cys11]mastoparan to Go. J. Biol. Chem. 266:1991;12655-12661.
41. Hillard C.J., Edgemond W.S., Campbell W.B. Characterization of ligand binding to the cannabinoid receptor of rat brain membranes using a novel method: application to anandamide. J. Neurochem. 64:1995;677-683.
42. Houston D.B., Howlett A.C. Solubilization of the cannabinoid receptor from rat brain and its functional interaction with guanine nucleotide-binding proteins. Mol. Pharmacol. 43:1993;17-22.
43. Howlett A.C. Cannabinoid inhibition of adenylate cyclase. Biochemistry of the response in neuroblastoma cell membranes. Mol. Pharmacol. 27:1985;429-436.
44. Howlett A.C. Cannabinoid inhibition of adenylate cyclase: relative activity of constituents and metabolites of marihuana. Neuropharmacology. 26:1987;507-512.
45. 1 cannabinoid receptor in the brain. Neurobiol. Dis. 5:1998;405-416.
46. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., Felder C.C., Herkenham M., Mackie K., Martin B.R., Mechoulam R., Pertwee R.G. International union of pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 54:2002;161-202.
47. Howlett, A.C., Evans, D.M., Houston, D.B., 1992. The cannabinoid receptor. In: Murphy, L.L., Bartke, A. (eds), Marihuana/Cannabinoids: Nuerobiology and Neurophysiology, CCR Press, Boca Raton, pp. 35-72.
48. Howlett A.C., Fleming R.M. Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes. Mol. Pharmacol. 26:1984;532-538.
49. Howlett A.C., Johnson M.R., Melvin L.S., Milne G.M. Nonclassical cannabinoid analgetics inhibit adenylate cyclase: development of a cannabinoid receptor model. Mol. Pharmacol. 33:1988;297-302.
50. 1 receptor ligands. Life Sci. 65:1999;617-625.
51. Howlett A.C., Qualy J.M., Khachatrian L.L. Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. Mol. Pharmaco. 129:1986;307-313.
52. Howlett A.C., Scott D.K., Wilken G.H. Regulation of adenylate cyclase by cannabinoid drugs. Insights based on thermodynamic studies. Biochem. Pharmacol. 38:1989;3297-3304.
53. 1 cannabinoid receptors using receptor peptide fragments and site-directed antibodies. Mol. Pharmacol. 53:1998;504-510.
54. Jacobsson S.O., Wallin T., Fowler C.J. Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors. J. Pharmacol. Exp. Ther. 299:2001;951-959.
55. 1 receptor. Eur. J. Pharmacol. 334:1997;Rl-R2.
56. Lu R., Hubbard J.R., Martin B.R., Kalimi M.Y. Roles of sulthydryl and disulfide groups in the binding of CP-55,940 to rat brain cannabinoid receptor. Mol. Cell Biochem. 121:1993;119-126.
57. Mackie K., Devane W.A., Hille B. Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol. Pharmacol. 44:1993;498-503.
58. Mackie K., Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc. Natl. Acad. Sci. USA. 89:1992;3825-3829.
59. Margulies J.E., Hammer R.P. Jr. Delta 9-tetrahydrocannabinol alters cerebral metabolism in a biphasic, dose-dependent manner in rat brain. Eur. J. Pharmacol. 202:1991;373-378.
60. McVey M., Hill J., Howlett A., Klein C. Adenylyl cyclase, a coincidence detector for nitric oxide. J. Biol. Chem. 274:1999;18887-18892.
61. Melvin L.S., Johnson M.R. Structure-activity relationships of tricyclic and nonclassical bicyclic cannabinoids. NIDA Res. Monogr. 79:1987;31-47.
62. Meschler J.P., Kraichely D.M., Wilken G.H., Howlett A.C. Inverse agonist properties of N-(piperidin-1-y1)-5-(4-chloropheny1)-1-(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCl (SRl41716A) and 1-(2-chlorophenyl)-4-cyano-5-(4-methoxyphenyl)-IH-pyrazole-3-carboxyl is acid phenylamide (CP-272871) for the CB(1)cannabinoid receptor. Biochem. Pharmacol. 60:2000;1315-1323.
63. Milligan G., Grassie M.A., Wise A., MacEwan D.J., Magee A.I., Parenti M. G-protein pahnitoylation: regulation and functional significance. Biochem. Soc. Trans. 23:1995;583-587.
64. 1 cannabinoid receptor C-terminal juxtamembrane region: structural requirements determined by peptide analysis. Biochemistry. 38:1999;3447-3455.
65. 1 receptor-G protein association. Subtype selectivity is determined by distinct intracellular domains. Eur. J. Biochem. 268:2001;499-505.
66. 1 cannabinoid receptor juxtamembrane C-terminal peptide confers activation to specific G proteins in brain. Mol. Pharmacol. 57:2000;162-170.
67. Mullaney I., Magee A.I., Unson C.G., Milligan G. Differential regulation of amounts of the guanine-nucleotide-binding proteins Gi and Go in neuroblastoma x glioma hybrid cells in response to dibutyryl cyclic AMP. Biochem. J. 256:1988;649-656.
68. Mumby S.M., Muntz K.H. Receptor regulation of G protein palmitoylation. Biochem. Soc. Trans. 23:1995;156-160.
69. 1 cannabinoid receptor mediate G protein coupling. Neuroscience. 107:2001;161-167.
70. Pahan K., Namboodiri A.M., Sheikh F.G., Smith B.T., Singh I. Increasing cAMP attenuates induction of inducible nitric-oxide synthase in rat primary astrocytes. J. Biol. Chem. 272:1997;7786-7791.
71. Pahan K., Raymond J.R., Singh I. Inhibition of phosphatidylinositol 3-kinase induces nitric-oxide synthase in lipopolysaccharide- or cytokine-stimulated C6 glial cells. J. Biol. Chem. 274:1999;7528-7536.
72. Palczewski K., Kumasaka T., Hori T., Behnke C.A., Motoshima H., Fox B.A., Le T.I., Teller D.C., Okada T., Stenkamp R.E., Yamamoto M., Miyano M. Crystal structure of rhodopsin: a G protein-coupled receptor. Science. 289:2000;739-745.
73. Piomelli D., Giuffrida A., Calignano A., Rodriguez D.F. The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol. Sci. 21:2000;218-224.
74. Prather P.L., Martin M.A., Breivogel C.S., Childers S.R. Activation of cannabinoid receptors in rat brain by WIN55212-2 produces coupling to multiple G protein a-subunits with different potencies. Mol. Pharmacol. 57:2000;1000-1010.
75. Prevot V., Rialas C.M., Croix D., Salzet M., Dupouy J.P., Poulain P., Beauvillain J.C., Stefano G.B. Morphine and anandamide coupling to nitric oxide stimulates GnRH and CRF release from rat median eminence: neurovascular regulation. Brain Res. 790:1998;236-244.
76. Rhee M.H., Bayewitch M., Avidor-Reiss T., Levy R., Vogel Z. Cannabinoid receptor activation differentially regulates the various adenylyl cyclase isozymes. J. Neurochem. 71:1998;1525-1534.
77. Ross E.M., Higashijima T. Regulation of G-protein activation by mastoparans and other cationic peptides. Methods Enzymol. 237:1994;26-37.
78. Sanchez C., Galve-Roperh I., Canova C., Brachet P., Guzman M. Delta 9-tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Lett. 436:1998;6-10.
79. Sanchez C., Galve-Roperh I., Rueda D., Guzman M. Involvement of sphingomyelin hydrolysis and the mitogen-activated protein kinase cascade in the Delta 9-tetrahydrocannabinol-induced stimulation of glucose metabolism in primary astrocytes. Mol. Pharmacol. 54:1998;834-843.
80. 1 cannabinoid receptor of astrocytes is coupled to sphingomyelin hydrolysis through the adaptor protein fan. Mol. Pharmacol. 59:2001;955-959.
81. Sanchez C., Velasco G., Guzman M. Delta9-tetrahydrocannabinol stimulates glucose utilization in C6 glioma cells. Brain Res. 767:1997;64-71.
82. Sarne Y., Rubovitch V., Fields A., Gafni M. Dissociation between the inhibitory and stimulatory effects of opioid peptides on cAMP formation in SK-N-SH neuroblastoma cells. Biochem. Biophys. Res. Commun. 246:1998;128-131.
83. Schubert D., Humphreys S., Baroni C., Cohn M. In vitro differentiation of a mouse neuroblastoma. Proc. Natl. Acad. Sci. USA. 64:1969;316-323.
84. Shim J.Y., Collantes E.R., Welsh W.J., Subramaniam B., Howlett A.C., Eissenstat M.A., Ward S.J. Three-dimensional quantitative structure-activity relationship study of the cannabimimetic (aminoalkyl) indoles using comparative molecular field analysis. J. Med. Chem. 41:1998;4521-4532.
85. Shim, J.Y., Howlett A.C., 2002. Prediction of the Binding Conformation of the Potent Aminialkylindole Agonist WIN55212-2 in the Brain Cannabinoid Receptor. 2002 American Chemical Society Abstracts.
86. 1 cannabinoid receptor-based molecular superposition model for canabimimetics Symposium on the Cannabinoids, Burlington, VT, International Cannabinoid Research Society.
87. 1 antagonist SR 141716A. J. Biol. Chem. 271:1996;6941-6946.
88. Simmons M.L., Murphy S. Induction of nitric oxide synthase in glial cells. J. Neurochem. 59:1992;897-905.
89. Song Z.H., Bonner T.I. A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212-2. Mol. Pharmacol. 49:1996;891-896.
90. Sugimoto K., Fujii S., Takemasa T., Yamashita K. Detection of intracellular nitric oxide using a combination of aldehyde fixatives with 4,5-diaminofluorescein diacetate. Histochem. Cell Biol. 113:2000;341-347.
91. 2+ transient in NG108-15 cells. J. Biochem. (Tokyo). 122:1997;890-895.
92. Sugiura T., Kodaka T., Kondo S., Tonegawa T., Nakane S., Kishimoto S., Yamashita A., Waku K. Inhibition by 2-arachidonoylglycerol, a novel type of possible neuromodulator, of the depolarization-induced increase in intracellular free calcium in neuroblastoma x glioma hybrid NG108-15 cells. Biochem. Biophys. Res. Commun. 233:1997;207-210.
93. 1 receptor is a 2-arachidonoylglycerol receptor. Structure-activity relationship of 2-arachidonoylglycerol, ether-linked analogues, and related compounds. J. Biol. Chem. 274:1999;2794-2801.
94. 2+-dependent transacylase and phosphodiesterase activities. Biochem. Biophys. Res. Commun. 218:1996;113-117.
95. Sunahara R.K., Dessauer C.W., Gilman A.G. Complexity and diversity of mammalian adenylyl cyclases. Annu. Rev. Pharmacol. Toxicol. 36:1996;461-480.
96. Syapin P.J., Koss J.S., Cutler C.Y. Inducible nitric oxide synthase expression in mesencephalic astrocyte cultures. Proc. West Pharmacol. Soc. 44:2001;117-119.
97. Twitchell W., Brown S., Mackie K. Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. J. Neurophysiol. 78:1997;43-50.
98. Venance L., Sagan S., Giaume C. (R)-methanandamide inhibits receptor-induced calcium responses by depleting internal calcium stores in cultured astrocytes. Pflugers. Arch. 434:1997;147-149.
99. Wang Y., Windh R.T., Chen C.A., Manning D.R. N-Myristoylation and betagamma play roles beyond anchorage in the palmitoylation of the G protein alpha(o) subunit. J. Biol. Chem. 274:1999;37435-37442.